Clinical

Dataset Information

0

PS-341 in Treating Patients With Advanced Solid Tumors or Lymphoma

ABSTRACT: RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of PS-341 in treating patients who have advanced solid tumors or lymphoma that have not responded to previous treatment.

DISEASE(S): Small Intestine Cancer,Angioimmunoblastic T-cell Lymphoma,Lymphoma,Intestinal Neoplasms,Unspecified Adult Solid Tumor, Protocol Specific

PROVIDER: 2003447 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

Json Xml

Similar Datasets

Clinical Combination Chemotherapy With or Without Biological Therapy in Treating Patients With Refractory Solid Tumor or Lymphoma
| 2004126 | ecrin-mdr-crc
Clinical Chemotherapy in Treating Patients With Solid Tumors
| 2002684 | ecrin-mdr-crc
Clinical ZD0473 and Doxorubicin in Treating Patients With Advanced Solid Tumors or Lymphoma
| 2006171 | ecrin-mdr-crc
Clinical Irinotecan in Treating Patients With Solid Tumors or Lymphoma Who Have Abnormal Liver or Kidney Function or Who Have Received Radiation Therapy to the Pelvis
| 2002903 | ecrin-mdr-crc
Clinical Suberoylanilide Hydroxamic Acid in Treating Patients With Advanced Solid Tumors That Have Not Responded to Previous Therapy
| 2004721 | ecrin-mdr-crc
Clinical Irinotecan and Capecitabine in Treating Patients With Solid Tumors
| 2003342 | ecrin-mdr-crc
Clinical Irinotecan Plus Cyclosporine and Phenobarbital in Treating Patients With Solid Tumors or Lymphoma
| 2002394 | ecrin-mdr-crc
Clinical 17-Dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG) in Treating Patients With an Advanced Solid Tumor or Lymphoma
| 2011214 | ecrin-mdr-crc
Clinical Genetic Testing Plus Irinotecan in Treating Patients With Solid Tumors or Lymphoma
| 2003426 | ecrin-mdr-crc
Clinical Azacitidine Plus Phenylbutyrate in Treating Patients With Advanced or Metastatic Solid Tumors That Have Not Responded to Previous Treatment
| 2004726 | ecrin-mdr-crc